Targeting Cancer. Transforming Therapies.
Revolutionary science meets transformative cancer therapy
Seattle Genetics is the largest global oncology biotechnology company based in the Pacific Northwest. We are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer.
Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency.
We have one marketed product, ADCETRIS® (brentuximab vedotin), which is the first in a new class of ADCs, commercially available in more than 65 countries worldwide for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). It is approved for two additional indications in the U.S.
We also are advancing two late-stage ADCs, enfortumab vedotin for urothelial cancer under our collaboration with Astellas, and tisotumab vedotin for cervical cancer under our collaboration with Genmab, each in potentially registrational clinical trials. We have multiple ongoing and planned clinical trials with ladiratuzumab vedotin (SGN-LIV1A) for breast cancer. Our programs are designed to address significant unmet medical needs and to improve treatment outcomes for patients.
With multiple global product opportunities, significant research into advancing ADC technology and an emerging complementary immuno-oncology technology, we are positioned to transform cancer therapy.